Genelux Corporation is a leading immuno-oncology company dedicated to addressing unmet medical needs in the field of cancer treatment. With a strong focus on developing immunotherapeutics, Genelux aims to stimulate personalized immune system responses to fight cancer on an individual basis. Their vision is to redefine the immuno-oncology space through the discovery and development of next-generation oncolytic viruses.

The company's strategy revolves around leveraging their deep internal capabilities in the clinical development of oncolytic virotherapies to create innovative immunotherapy solutions. They are committed to advancing their leading product candidate, Olvi-Vec, through clinical development and seeking regulatory approval. Additionally, Genelux supports collaborative partners in the development of proprietary viral products for human and non-human animal use.

With a diverse pipeline of product candidates, Genelux is focused on developing treatments for a broad range of cancers, including solid tumors that are notoriously difficult to treat. They also strive to build partnerships and collaborations to further enhance the development and commercialization of their products. Headquartered in Southern California, Genelux operates in the Los Angeles region, an emerging biotech hub, and has research and manufacturing facilities in San Diego, one of the premier biotech hubs in the United States.

Driven by their vision and mission, Genelux is committed to improving outcomes for cancer patients, particularly those with limited therapeutic options, through the development of innovative and accessible anticancer drug candidates